Brought to you by

Celgene buys Pharmion for $2.6bn in cash and stock
20 Nov 2007
Executive Summary
Hematology and oncology immunotherapeutics company Celgene has agreed to purchase Pharmion (cancer treatments) for $2.7bn in cash and stock ($2.6bn net transaction value after subtracting Pharmion's net cash, according to the M&A conference call). Celgene will pay $25 in cash and, based on the current stock prices, $47 in its own stock, for each of Pharmion's outstanding shares; the exact share ratio will be determined when the deal closes. The total $72 per share price is a 45% premium to Pharmion's preannouncement market average.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Intra-Biotech Deal
- Payment Includes Cash
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com